Moderna Stock Price, News & Analysis

Moderna announced the FDA's Emergency Use Authorization (EUA) for its COVID-19 vaccine booster dose (mRNA-1273) at a 50 µg level. The EUA is for individuals aged 65 and older, and at-risk individuals aged 18 to 64, with administration recommended at least six months post-primary vaccination. The authorization also allows a booster for those previously vaccinated with other COVID-19 vaccines. The decision is based on strong clinical evidence indicating effective immune response post-booster, with unanimous support from the FDA's advisory committee.

Moderna announced a positive, unanimous vote from the FDA's VRBPAC to recommend Emergency Use Authorization for a 50 µg booster dose of its COVID-19 vaccine (mRNA-1273) for individuals aged 65 and older and high-risk adults aged 18 to 64. This vote may enable up to 1 billion additional doses in 2022. The recommendation was based on strong clinical data demonstrating higher antibody responses against COVID-19 variants. The FDA will consider this recommendation for final authorization, followed by a CDC review.

Moderna, Inc. (NASDAQ: MRNA) will host a live conference call and webcast on November 4, 2021, at 8:00 a.m. ET to discuss its Q3 2021 financial results and provide a corporate update. Interested parties can participate by calling 866-922-5184 (domestic) or 409-937-8950 (international) with conference ID 9177025. A webcast will be available on the Moderna Investors website and archived for a year. Moderna has rapidly advanced its mRNA therapeutics, particularly in COVID-19 vaccines, showcasing significant growth in the biotech field.

Moderna announced a significant agreement with COVAX to supply an additional 176.5 million doses of its COVID-19 vaccine. The doses are priced at an average of less than $10 per 100 µg dose, aligning with Moderna's global access principles. Additionally, the company has requested regulatory authorization for a 50 µg booster dose, which could enhance supply for low-income countries. COVAX has already secured over 210 million doses, with options for further purchases. This partnership aims to promote equitable vaccine access worldwide.

Moderna (NASDAQ: MRNA) is set to invest up to $500 million in building a state-of-the-art mRNA manufacturing facility in Africa. This facility aims to produce up to 500 million vaccine doses annually. The investment reflects Moderna's commitment to expanding its global manufacturing capacity and enhancing its mRNA platform, which has been pivotal in COVID-19 vaccine production. The company plans to begin the site selection process soon. Moderna has delivered over 500 million doses of its COVID-19 vaccine globally to date.

Moderna (NASDAQ: MRNA) has launched the Moderna Fellowship Program aimed at fostering a new generation of leaders in mRNA therapeutics and vaccine research. The initiative will select approximately 50 global fellows in its first year, focusing on infectious diseases. Dr. Greg Poland, an expert in infectious diseases, will chair the program. This effort underscores Moderna's commitment to supporting independent research and advancing mRNA-based innovations to improve patient care and population health.

Moderna, Inc. (NASDAQ: MRNA) announced that the European Medicines Agency has authorized a third dose of its COVID-19 vaccine, Spikevax, for severely immunocompromised individuals aged 12 years and older, to be administered at least 28 days after the second dose. Recent studies indicate that a third dose may enhance immune response in this vulnerable population. Moderna reaffirms its commitment to combatting COVID-19 through its mRNA technology, which has yielded effective vaccines and therapeutics.

Moderna, Inc. (NASDAQ: MRNA) has announced plans to invest in a new 462,000 sq. ft. science center in Cambridge, Massachusetts, aiming for LEED Zero certification. This facility will support its mRNA therapeutics and vaccines, focusing on sustainability and collaboration. Construction has begun, with phased move-in expected in 2023. Alexandria Real Estate Equities (NYSE: ARE) is the development partner, while Jones Lang LaSalle (NYSE: JLL) facilitated the site selection. Moderna's pipeline includes 37 programs, 22 of which are in clinical studies.

Moderna (Nasdaq: MRNA) announced that President Stephen Hoge, M.D., will join a fireside chat at Chardan’s Virtual 5th Annual Genetic Medicines Conference on October 5 at 1:00 p.m. ET. Investors can access a live webcast of the event on Moderna's website under “Events and Presentations.” The discussion will be archived for 30 days post-event. Moderna has evolved significantly in its 10 years, focusing on mRNA therapeutics and vaccines, including COVID-19, and has built a diverse clinical portfolio alongside robust manufacturing capabilities.